Flechtner Jessica Baker 4
4 · GENOCEA BIOSCIENCES, INC. · Filed Mar 17, 2021
Insider Transaction Report
Form 4
Flechtner Jessica Baker
Chief Scientific Officer
Transactions
- Award
Common Stock
[F1]2021-03-15+43,750→ 43,750 total - Award
Stock Option (Right to Buy)
[F2]2021-03-15+131,250→ 131,250 totalExercise: $3.01Exp: 2031-03-15→ Common Stock (131,250 underlying) - Award
Restricted Stock Unit
[F3][F4]2021-03-15+100,000→ 100,000 total→ Common Stock (100,000 underlying)
Footnotes (4)
- [F1]Restricted stock units that represent the contingent right to receive, at settlement, one share of common stock. The restricted stock units are scheduled to vest 25% on each of the first four anniversaries of the grant date.
- [F2]The options are scheduled to vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date.
- [F3]Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- [F4]Vesting of these restricted stock units depends on the average closing price of a share of Genocea Biosciences, Inc.'s common stock over the sixty trading days immediately preceding December 31, 2023. The"target" number of restricted stock units is reported. Between 75% and 150% of the target number of units may vest on December 31, 2023, with the vesting percentage determined based on actual performance.
Signature
/s/ DIANTHA DUVALL, ATTORNEY-IN-FACT FOR JESSICA FLECHTNER|2021-03-17